- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Ovarian Carcinosarcoma, Advanced Ovarian Clear Cell Adenocarcinoma, Advanced Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian High Grade Serous Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Primary Peritoneal High Grade Serous Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Mixed Cell Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Leukapheresis, Magnetic Resonance Imaging, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, Placebo Administration, Tetanus and Diphtheria Toxoids Adsorbed
- Procedure · Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 7,622
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumor
- Interventions
- Topotecan, Sorafenib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Hartford, Connecticut • Wilmington, Delaware + 6 more
- Conditions
- COVID-19
- Interventions
- Baricitinib, Dexamethasone, Placebo, Remdesivir
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1,010 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more
- Conditions
- Breast Cancer, Hot Flashes
- Interventions
- pregabalin, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 207 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2015
- U.S. locations
- 209
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 135 more
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
- Interventions
- ASC30 tablets A1, Placebo
- Drug
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 84
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 80 more
- Conditions
- Tinea Pedis, Athlete's Foot
- Interventions
- Econazole Nitrate Foam 1%, Vehicle Foam, Econazole Nitrate Cream 1%, Placebo Cream
- Drug · Other
- Lead sponsor
- AmDerma
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 12
- States / cities
- Fremont, California • Hockessin, Delaware • Boca Raton, Florida + 9 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Best Supportive Care, BI 836858
- Procedure · Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Tampa, Florida • Cleveland, Ohio
- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Placebo, Nemolizumab
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 941 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 57
- States / cities
- North Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 48 more
- Conditions
- Thrombosis, Deep Vein, Iliofemoral; Thrombosis
- Interventions
- Perivascular dexamethasone, Perivascular sham
- Combination Product
- Lead sponsor
- Mercator MedSystems, Inc.
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Orange, California • Darien, Connecticut + 16 more
- Conditions
- Breast Cancer
- Interventions
- exemestane
- Drug
- Lead sponsor
- NCIC Clinical Trials Group
- Network
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 4,560 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2018
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • La Jolla, California + 34 more
- Conditions
- Depressive Disorder, Major
- Interventions
- SEP-225289, Venlafaxine, placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 523 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 51
- States / cities
- Little Rock, Arkansas • Arcadia, California • Beverly Hills, California + 43 more
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
- Interventions
- Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 3,154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2021
- U.S. locations
- 208
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
- Conditions
- Solid Tumor Malignancy
- Interventions
- Pemigatinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 44
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- Danicamtiv, Midazolam
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 5
- States / cities
- Fort Lauderdale, Florida • Inverness, Florida • Jacksonville, Florida + 2 more
- Conditions
- Overweight, Obesity
- Interventions
- Eloralintide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 52 more
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- COVID-19 Vaccine
- Biological
- Lead sponsor
- GI Alliance
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Baton Rouge, Louisiana • Southlake, Texas + 1 more
- Conditions
- Contraception
- Interventions
- DR-1011
- Drug
- Lead sponsor
- Duramed Research
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 2,235 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 55
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
- Conditions
- Atherosclerosis
- Interventions
- MLDL1278A, placebo, statin, stable dose
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 22
- States / cities
- Torrance, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 15 more
- Conditions
- Sarcopenia
- Interventions
- REGN1033 (SAR391786), placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 70 Years and older
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 33
- States / cities
- Anniston, Alabama • Phoenix, Arizona • El Cajon, California + 30 more
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Interventions
- Setidegrasib, Oxaliplatin, Leucovorin, Irinotecan, fluorouracil, liposomal irinotecan, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 49
- States / cities
- Tucson, Arizona • Fort Smith, Arkansas • Fullerton, California + 43 more
- Conditions
- Lung Cancer, Non Small Cell Lung Carcinoma
- Interventions
- Pemetrexed, Matuzumab
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 42
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 36 more
- Conditions
- Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia
- Interventions
- Inclisiran, Evolocumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
- Conditions
- Contraception
- Interventions
- Levonorgestrel (BAY98-7196)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 1,471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 79
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 67 more
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Low Grade Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Hodgkin Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Hodgkin Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Soft Tissue Sarcoma, Rhabdoid Tumor, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Wilms Tumor
- Interventions
- Tazemetostat
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more